New Mesothelioma Treatment Recommendations Released in 2026: What Patients and Families Should Know
July 21, 2026
Mesothelioma remains one of the most challenging cancers to treat. Closely linked to asbestos exposure, this aggressive cancer often progresses despite standard therapies, leaving patients with limited options when the disease returns. However, a groundbreaking new study published in Nature Communications suggests a promising new treatment approach may be on the horizon.
In the report, Preclinical Characterization and Phase 1 Clinical Testing of Targeting Mitochondrial Peroxiredoxin 3 in Cancer, researchers led by Victoria Gibson, Joanna Dzialo, Terri Messier, James Spicer, Dean A. Fennell, and Brian Cunniff investigated a novel strategy that targets a critical antioxidant defense mechanism used by cancer cells to survive. Their findings demonstrated both encouraging laboratory results and promising early clinical outcomes in patients with relapsed pleural mesothelioma.
Understanding Mesothelioma's Dependence on Oxidative Stress
Cancer cells live under constant oxidative stress. As they grow and divide rapidly, they produce increased levels of reactive oxygen species (ROS)—unstable molecules capable of damaging cellular structures. While excessive ROS can kill cancer cells, tumors often adapt by strengthening their antioxidant defenses.
Mesothelioma appears particularly dependent on these protective systems. According to the researchers, mesothelioma tumors are characterized by elevated oxidative stress and increased expression of genes that help cancer cells escape oxidative damage.
One of the most important components of this defense system is a protein known as peroxiredoxin 3 (PRX3), which resides within mitochondria and helps regulate ROS levels. As the authors explain, “PRX3, a mitochondrial antioxidant enzyme, regulates reactive oxygen species homeostasis and promotes tumor cell survival.”
The study explored what happens when PRX3 is disabled.
A New Therapeutic Target: PRX3
Researchers used both genetic and drug-based approaches to suppress PRX3 activity. In laboratory experiments, they genetically removed the PRX3 gene from mesothelioma cells and observed dramatic effects.
PRX3 deletion reduced cell proliferation, impaired mitochondrial function, and prevented tumors from forming in animal models. Most notably, the researchers found that mesothelioma cells lacking PRX3 failed to develop measurable tumors when implanted into mice.
The findings suggest that PRX3 is not simply helpful to mesothelioma cells—it may be essential for tumor growth and survival.
As the researchers concluded:
“PRX3 knockout or pharmacological inhibition of PRX3 is tumor suppressive in vitro and in vivo in mesothelioma models.”
Thiostrepton and the Development of RSO-021
The study centered on a naturally derived compound called thiostrepton (TS), which inhibits PRX3. Thiostrepton disrupts the cancer cell's ability to manage oxidative stress, eventually leading to cell death.
To make thiostrepton suitable for clinical use, the researchers developed a formulation known as RSO-021. This therapy was administered directly into the pleural space—the area surrounding the lungs where pleural mesothelioma typically develops.
Delivering the drug directly to the tumor site offers several advantages:
- Higher concentrations can reach the cancer.
- Systemic exposure may be minimized.
- Researchers can monitor treatment effects directly in the pleural space.
- Potential side effects may be reduced compared with intravenous therapies.
This localized approach became the basis for the Phase 1 clinical trial.
Exciting Results from Patient-Derived Tumor Samples
Before moving into human trials, the team tested thiostrepton in tumor tissue samples obtained from mesothelioma patients.
The drug successfully triggered apoptosis—programmed cell death—in many of the patient-derived tumor explants. While responses varied between individual samples, the overall findings demonstrated that mesothelioma cells can be highly vulnerable to PRX3 inhibition.
Researchers also identified specific genetic characteristics that may influence treatment response. Tumors with alterations involving the BAP1 and SETD2 genes appeared more likely to respond to PRX3 inhibition.
These observations could eventually help physicians identify patients most likely to benefit from this therapy.
Phase 1 Trial Demonstrates Safety and Early Signs of Effectiveness
Perhaps the most encouraging findings came from the first-in-human Phase 1 clinical trial known as MITOPE (NCT05278975).
The study enrolled patients with relapsed pleural mesothelioma who had already progressed after previous treatments. Researchers administered RSO-021 weekly through indwelling pleural catheters.
The trial found that the 90 mg dose was generally well tolerated and met the study's primary safety objectives.
Importantly, investigators reported evidence of clinical activity:
- Disease control was achieved in 67% of evaluable mesothelioma patients after 12 weeks.
- One patient achieved a partial response.
- Several patients experienced stable disease.
- Tumor reductions were observed.
- Pleural effusion volumes commonly decreased during treatment.
The authors summarized one of the key findings:
“Weekly local intrapleural treatment with the TS formulated drug product RSO-021 at 90 mg is well tolerated leading to disease control in 67% of patients at 12 weeks and is associated with tumor reductions.”
A particularly noteworthy response remained durable through week 30, with continued tumor shrinkage observed over time.
Why This Research Matters for Mesothelioma Patients
Mesothelioma treatment has evolved significantly in recent years, particularly with the introduction of immunotherapy. Yet many patients still experience disease progression, highlighting the urgent need for new treatment approaches.
What makes this study unique is that it targets a biological vulnerability specific to how mesothelioma cells manage oxidative stress.
Rather than directly attacking tumor DNA or stimulating immune responses, PRX3 inhibition essentially overwhelms cancer cells by removing one of their primary defense systems.
This strategy may open entirely new avenues for mesothelioma treatment, especially for patients whose disease no longer responds to standard therapies.
Overcoming Resistance: The Role of SLC7A11
The research team also uncovered a possible mechanism of resistance.
They identified a protein called SLC7A11 that appears to help some mesothelioma cells survive PRX3 inhibition. Tumors with higher SLC7A11 expression were generally less sensitive to treatment.
However, this discovery presents an opportunity. Laboratory experiments showed that blocking SLC7A11 enhanced the effectiveness of thiostrepton and increased cancer cell death.
Future treatment strategies may involve combining PRX3 inhibitors with therapies that target SLC7A11, potentially improving outcomes even further.
Looking Ahead
The findings from this study represent an important step forward in mesothelioma research. While larger clinical trials will be needed to confirm efficacy, the results suggest that targeting PRX3 may offer a promising new therapeutic approach.
As the researchers concluded:
“PRX3 inhibition is a tractable therapeutic target in mesothelioma.”
The successful completion of this Phase 1 trial provides a foundation for future studies and raises hope that patients facing relapsed mesothelioma may soon have additional treatment options.
To access a full version of the report, click here.